{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:52:18Z","timestamp":1744905138106},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11033-023-08511-4","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T06:02:20Z","timestamp":1684562540000},"page":"5687-5695","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms"],"prefix":"10.1007","volume":"50","author":[{"given":"It\u0131r \u015eirino\u011flu","family":"Demiriz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Hanifi","family":"Kazanci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Menfaatli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davoud","family":"Jafari-Gharabaghlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nosratollah","family":"Zarghami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"issue":"1","key":"8511_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0898-6568(99)00063-7","volume":"12","author":"T Bittorf","year":"2000","unstructured":"Bittorf T, Seiler J, L\u00fcdtke B, B\u00fcchse T, Jaster R, Brock J (2000) Activation of STAT5 during EPO-directed suppression of apoptosis. Cell Signal 12(1):23\u201330","journal-title":"Cell Signal"},{"issue":"10","key":"8511_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1947601910397187","volume":"1","author":"SS Jatiani","year":"2010","unstructured":"Jatiani SS, Baker SJ, Silverman LR, Reddy EP (2010) Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 1(10):979\u2013993","journal-title":"Genes Cancer"},{"issue":"2","key":"8511_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.neuron.2011.11.024","volume":"73","author":"CS Nicolas","year":"2012","unstructured":"Nicolas CS, Peineau S, Amici M, Csaba Z, Fafouri A, Javalet C et al (2012) The Jak\/STAT pathway is involved in synaptic plasticity. Neuron 73(2):374\u2013390","journal-title":"Neuron"},{"issue":"1","key":"8511_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"key":"8511_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3389\/fphar.2022.821344","volume":"13","author":"B Rah","year":"2022","unstructured":"Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M et al (2022) JAK\/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. Front Pharmacol 13:610","journal-title":"Front Pharmacol"},{"issue":"12","key":"8511_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"K Yamaoka","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt VE, Silvennoinen O, O\u2019Shea JJ (2004) The janus kinases (jaks). Genome Biol 5(12):1\u20136","journal-title":"Genome Biol"},{"issue":"10","key":"8511_CR7","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","volume":"107","author":"RL Levine","year":"2006","unstructured":"Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al (2006) X-inactivation\u2013based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107(10):4139\u20134141","journal-title":"Blood"},{"issue":"9","key":"8511_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJM199802263380902","volume":"338","author":"M Silva","year":"1998","unstructured":"Silva M, Richard C, Benito A, Sanz C, Olalla I, Fern\u00e1ndez-Luna JL (1998) Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338(9):564\u2013571","journal-title":"N Engl J Med"},{"issue":"9","key":"8511_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi A, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"key":"8511_CR10","doi-asserted-by":"crossref","unstructured":"Kandu\u0142a Z, Janowski M, Wi\u0119ckowska B, Paczkowska E, Lewandowski K (2022) JAK2 V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. Journal of Cancer Research and Clinical Oncology. :1\u201315","DOI":"10.1007\/s00432-022-04327-0"},{"key":"8511_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","volume":"91","author":"F Delhommeau","year":"2010","unstructured":"Delhommeau F, Jeziorowska D, Marzac C, Casadevall N (2010) Molecular aspects of myeloproliferative neoplasms. Int J Hematol 91:165\u2013173","journal-title":"Int J Hematol"},{"issue":"15","key":"8511_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R et al (2018) Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 379(15):1416\u20131430","journal-title":"N Engl J Med"},{"issue":"25","key":"8511_CR13","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"25","key":"8511_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405","journal-title":"N Engl J Med"},{"issue":"10","key":"8511_CR15","first-page":"1544","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood J Am Soc Hematol 123(10):1544\u20131551","journal-title":"Blood J Am Soc Hematol"},{"issue":"10","key":"8511_CR16","first-page":"1552","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood J Am Soc Hematol 123(10):1552\u20131555","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"8511_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho T, Finke C, Knudson R, Ketterling R, Hanson C et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472\u20131477","journal-title":"Leukemia"},{"issue":"24","key":"8511_CR18","first-page":"3714","volume":"123","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood J Am Soc Hematol 123(24):3714\u20133719","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"8511_CR19","first-page":"1703","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood J Am Soc Hematol 115(9):1703\u20131708","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"8511_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"3","key":"8511_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"S MWer","year":"1988","unstructured":"MWer S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215","journal-title":"Nucleic Acids Res"},{"issue":"9501","key":"8511_CR22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The Lancet 366(9501):1945\u20131953","journal-title":"The Lancet"},{"issue":"3","key":"8511_CR23","first-page":"1013","volume":"110","author":"S Dupont","year":"2007","unstructured":"Dupont S, Mass\u00e9 A, James C, Teyssandier I, L\u00e9cluse Y, Larbret F et al (2007) The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood J Am Soc Hematol 110(3):1013\u20131021","journal-title":"Blood J Am Soc Hematol"},{"issue":"10","key":"8511_CR24","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1080\/10428190802290652","volume":"49","author":"E Lucia","year":"2008","unstructured":"Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M et al (2008) The incidence of JAK2 V617F mutation in bcr\/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Leuk Lymphoma 49(10):1907\u20131915","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"8511_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3324\/haematol.12337","volume":"93","author":"Z Xiao","year":"2008","unstructured":"Xiao Z, Zhang Y, Li L, Nie L, Yang L, Xu S (2008) The Janus kinase 2 (JAK2) V617F mutation in chinese patients with chronic myeloproliferative disorders. Haematologica 93(5):787\u2013788","journal-title":"Haematologica"},{"issue":"9","key":"8511_CR26","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"A Vannucchi","year":"2007","unstructured":"Vannucchi A, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21(9):1952\u20131959","journal-title":"Leukemia"},{"issue":"6","key":"8511_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","volume":"79","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Pallisgaard N, M\u00f8ller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2013impact on disease phenotype. Eur J Haematol 79(6):508\u2013515","journal-title":"Eur J Haematol"},{"issue":"3","key":"8511_CR28","first-page":"840","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al (2007) Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood J Am Soc Hematol 110(3):840\u2013846","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"8511_CR29","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Strand J, Lasho T, Knudson R, Finke C, Gangat N et al (2007) Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21(9):2074\u20132075","journal-title":"Leukemia"},{"issue":"2","key":"8511_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D et al (2005) Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131(2):166\u2013171","journal-title":"Br J Haematol"},{"issue":"1","key":"8511_CR31","first-page":"162","volume":"29","author":"O Akay","year":"2009","unstructured":"Akay O, Yasar N, \u00dcSK\u00dcDAR TEKE H, MUTLU F, Gulbas Z, (2009) Retrospective analysis of 111 cases with chronic myeloproliferative disorders: clinical features and survival. TURKIYE KLINIKLERI TIP BILIMLERI DERGISI 29(1):162\u2013168","journal-title":"TURKIYE KLINIKLERI TIP BILIMLERI DERGISI"},{"issue":"10","key":"8511_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755\u2013761","journal-title":"Am J Med"},{"issue":"3","key":"8511_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","volume":"66","author":"P Fenaux","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer 66(3):549\u2013556","journal-title":"Cancer"},{"issue":"12","key":"8511_CR34","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S et al (2020) Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv 4(12):2567\u20132576","journal-title":"Blood Adv"},{"issue":"9","key":"8511_CR35","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.31557\/APJCP.2020.21.9.2805","volume":"21","author":"KS Yow","year":"2020","unstructured":"Yow KS, Liu X, Chai CN, Tung ML, Yan B, Christopher D et al (2020) Relationship of JAK2 (V617F) allelic burden with clinico-haematological manifestations of Philadelphia-negative myeloproliferative neoplasms. Asian Pac J Cancer Prevention: APJCP 21(9):2805","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"Supplement 1","key":"8511_CR36","doi-asserted-by":"publisher","first-page":"12270","DOI":"10.1182\/blood-2022-168835","volume":"140","author":"S Naseem","year":"2022","unstructured":"Naseem S, Rastogi P, Jain A, Malhotra P (2022) Study of JAK2 V617F allele Burden by Droplet Digital PCR in BCR-ABL1 negative myeloproliferative neoplasms and its implications on Disease phenotype. Blood 140(Supplement 1):12270","journal-title":"Blood"},{"key":"8511_CR37","unstructured":"Al-Rubaie HA, Al-Bayaa IM, Al-Musawi BM The impact of JAK2V617F allelic burden on clinical and laboratory parameters in patients with myeloproliferative neoplasms"},{"key":"8511_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","volume":"101","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y et al (2015) Consequences of the JAK2 V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol 101:148\u2013153","journal-title":"Int J Hematol"},{"issue":"02","key":"8511_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/sajc.sajc_161_18","volume":"8","author":"S Sazawal","year":"2019","unstructured":"Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R (2019) Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: a study from India. South Asian J Cancer 8(02):127\u2013129","journal-title":"South Asian J Cancer"},{"issue":"3","key":"8511_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.14740\/jocmr2047w","volume":"7","author":"I Yonal-Hindilerden","year":"2015","unstructured":"Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS et al (2015) The burden of JAK2V617F mutated allele in turkish patients with myeloproliferative neoplasms. J Clin Med Res 7(3):161","journal-title":"J Clin Med Res"},{"issue":"6","key":"8511_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/10245332.2016.1267830","volume":"22","author":"L Hu","year":"2017","unstructured":"Hu L, Pu L, Ding Y, Li M, Cabanero M, Xie J et al (2017) Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. Hematology 22(6):354\u2013360","journal-title":"Hematology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08511-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08511-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08511-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:50:12Z","timestamp":1687557012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08511-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["8511"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08511-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential competing interest was reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research protocol was evaluated and approved on 30.01.2020 by Bak\u0131rk\u00f6y Dr. Sadi Konuk Education and Research, Hospital Clinical Researches Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}